Tuesday, July 3, 2012

Alcortin A Gel





Dosage Form: gel
ALCORTIN® A gel

Prescribing Information



Alcortin A Gel Description


Each gram of Alcortin® A contains 2.0% (20 mg) Hydrocortisone Acetate and 1.0% (10 mg) Iodoquinol. Also contains 1.0% (10 mg) Aloe polysaccharide1. Other ingredients: Purified Water, Carbopol, Magnesium Aluminum Silicate, PPG-20 Methyl Glucose Ether, Aminomethyl Propanol, Propylene Glycol, Glycerine, Benzyl Alcohol, SD Alcohol 40 B, Biopeptide, Hydrochloric Acid, FD&C Blue # 1 and FD&C Yellow # 10.



1

U.S. Patents

#6,436,679; #6,271,214; #6,133,440; #5,708,038; patent pending


Iodoquinol


Iodoquinol is an antifungal and antibacterial agent. Chemically, Iodoquinol is [5,7-diiodo-8-quinolinol] with the molecular formula (C9H5I2NO) and is represented by the following structural formula:




Hydrocortisone Acetate


Hydrocortisone acetate is an anti-inflammatory and antipruritic agent. Chemically, hydrocortisone acetate is [Pregn-4-ene-3, 20-dione, 11, 17, 21- trihydroxy-, (11β)-] with the molecular formula (C21H30O5) and is represented by the following structural formula:




Alcortin A Gel - Clinical Pharmacology


Hydrocortisone Acetate has anti-inflammatory, antipruritic and vasoconstrictive properties. While the mechanism of anti-inflammatory activity is unclear, there is evidence to suggest that a recognizable correlation exists between vasoconstrictor potency and therapeutic efficacy in humans. Iodoquinol has both antifungal and antibacterial properties.



Pharmacokinetics


The extent of percutaneous absorption of topical steroids is determined by many factors including the vehicle, the integrity of the epidermal barrier and the use of occlusive dressings. Hydrocortisone acetate can be absorbed from normal intact skin. Inflammation and/or other inflammatory disease processes in the skin increase percutaneous absorption. Occlusive dressings substantially increase the percutaneous absorption of topical corticosteroids. Once absorbed through the skin, hydrocortisone acetate is metabolized in the liver and most body tissue to hydrogenated and degraded forms such as tetrahydrocortisone and tetrahydrocortisol. These are excreted in the urine, mainly conjugated as glucuronides, together with a very small proportion of unchanged hydrocortisone acetate. There are no data available regarding the percutaneous absorption of iodoquinol; however, following oral administration, 3-5% of the dose was recovered in the urine as a glucuronide.



Indications and Usage for Alcortin A Gel


Based on a review of a related drug by the National Research Council and subsequent FDA classification for that drug, the indications are as follows: "Possibly" Effective: Contact or atopic dermatitis; impetiginized eczema; nummular eczema; endogenous chronic infectious dermatitis; stasis dermatitis; pyoderma; nuchal eczema and chronic eczematoid otitis externa; acne urticata; localized or disseminated neurodermatitis; lichen simplex chronicus; anogenital pruritus (vulvae, scroti, ani); folliculitis; bacterial dermatoses; mycotic dermatoses such as tinea (capitis, cruris, corporis, pedis); monliasis; intertrigo. Final classification of the less-than-effective indications requires further investigation.



Contraindications


Alcortin A is contraindicated in those patients with a history of hypersensitivity to hydrocortisone acetate, iodoquinol, aloe vera, glycine, histidine, lysine, palmitic acid or any other components of the preparation.



Warnings and Precautions


For external use only. Keep away from eyes. If irritation develops, the use of Alcortin A should be discontinued and appropriate therapy instituted. Staining of the skin, hair and fabrics may occur. Not intended for use on infants or under diapers or occlusive dressings. If extensive areas are treated or if the occlusive dressing technique is used, the possibility exists of increased systemic absorption of the corticosteroid, and suitable precautions should be taken. Children may absorb proportionally larger amounts of topical corticosteroids and thus be more susceptible to systemic toxicity. Parents of pediatric patients should be advised not to use tight-fitting diapers or plastic pants on a child being treated in the diaper area, as these garments may constitute occlusive dressings. Iodoquinol may be absorbed through the skin and interfere with thyroid function tests. If such tests are contemplated, wait at least one month after discontinuance of therapy to perform these tests. The ferric chloride test for phenylketonuria (PKU) can yield a false positive result if iodoquinol is present in the diaper or urine. Prolonged use may result in overgrowth of non-susceptible organisms requiring appropriate therapy. Keep out of reach of children. Burning, itching, irritation and dryness have been reported infrequently following the use of topical corticosteroids.



Carcinogenesis, Mutagenisis and Impairment of Fertility


Long term animal studies have not been performed to evaluate the carcinogenic potential of the effect on fertility of hydrocortisone or iodoquinol. In vitro studies to determine mutagenicity with hydrocortisone have revealed negative results. Mutagenicity studies have not been performed with iodoquinol.


Pregnancy Category C

Animal reproductive studies have not been conducted with Alcortin A. It is not known whether Alcortin A can cause fetal harm when administered to pregnant women or can affect reproductive capacity. Alcortin A should be given to pregnant women only if clearly needed.



Nursing Mothers


It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Alcortin A is administered to a nursing woman.



Pediatric Use


Safety and effectiveness in pediatric patients under the age of 12 have not been established.



Adverse Reactions


The following local adverse reactions are reported infrequently with topical corticosteroids. These reactions are listed in an approximate decreasing order of occurrence. Burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, secondary infections, skin atrophy, striae and miliaria.



Alcortin A Gel Dosage and Administration


Apply to affected area 3-4 times daily in accordance with physician's directions or as directed otherwise by a physician.



How is Alcortin A Gel Supplied



FORM


48.0 gram carton of 24-count of 2.0 gram gel individual packs


NDC #68040-705-13


2.0 gram gel individual pack


NDC # 68040-705-02


10 count carton of 2.0 gram gel sample packs - not for resale


NDC # 68040-705-08


Each 2.0 gram gel pack contains multiple doses depending on the surface area treated.



STORAGE


Store at room temperature 15º-30ºC (59º-86ºF).


Keep tightly closed.



Rx only

www.alcortin.com


Distributed by:

Primus Pharmaceuticals, Inc.

Scottsdale, AZ 85251

www.primusrx.com


Manufactured by:

Sonar Products, Inc.

Carlstadt, NJ 07072


© 2007 Primus Pharmaceuticals, Inc. All rights reserved.

ISS. 1207 #00499



PRINCIPAL DISPLAY PANEL - 24 Pack Carton


NDC 68040-705-13

Rx only


Alcortin® A Gel

1% iodoquinol•2% hydrocortisone acetate

1% aloe polysaccharides


Anti-fungal • Anti-bacterial • Anti-inflammatory


24

PACK


Hygienic • Convenient

& Portable


Contains moisturizers • For dermatological use only


Biopeptide Aloe Complex™

Deeper Penetration

Patented Formula


Net Wt. 48.0 g (1.69 oz.) • 24 packs of 2.0g (0.07 oz.) each


Each pack contains multiple doses

(depending on the surface area treated)










ALCORTIN A 
hydrocortisone acetate, aloe vera leaf and iodoquinol  gel










Product Information
Product TypeHUMAN PRESCRIPTION DRUGNDC Product Code (Source)68040-705
Route of AdministrationTOPICALDEA Schedule    














Active Ingredient/Active Moiety
Ingredient NameBasis of StrengthStrength
HYDROCORTISONE ACETATE (HYDROCORTISONE)HYDROCORTISONE ACETATE20 mg  in 1 g
ALOE VERA LEAF (ALOE VERA LEAF)ALOE VERA LEAF10 mg  in 1 g
Iodoquinol (Iodoquinol)Iodoquinol10 mg  in 1 g





Inactive Ingredients
Ingredient NameStrength
No Inactive Ingredients Found


















Product Characteristics
ColorGREENScore    
ShapeSize
FlavorImprint Code
Contains      














Packaging
#NDCPackage DescriptionMultilevel Packaging
168040-705-1324 PACKET In 1 BOXcontains a PACKET (68040-705-02)
168040-705-021 g In 1 PACKETThis package is contained within the BOX (68040-705-13)










Marketing Information
Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
UNAPPROVED OTHER01/01/2010


Labeler - Primus Pharmaceuticals (130834745)

Registrant - Sonar Products, Inc (104283945)









Establishment
NameAddressID/FEIOperations
Sonar Products, Inc104283945MANUFACTURE
Revised: 10/2009Primus Pharmaceuticals

More Alcortin A Gel resources


  • Alcortin A Gel Side Effects (in more detail)
  • Alcortin A Gel Use in Pregnancy & Breastfeeding
  • Alcortin A Gel Drug Interactions
  • Alcortin A Gel Support Group
  • 0 Reviews for Alcortin A - Add your own review/rating


Compare Alcortin A Gel with other medications


  • Dermatitis
  • Eczema

No comments:

Post a Comment